Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc.
Your view on TSHA
Overview
What the company does, where it operates, and who runs it.
About Taysha Gene Therapies, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sean P. Nolan
- Headquarters
- 3000 Pegasus Park Drive, Dallas, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Sean P. Nolan
- Headquarters
- 3000 Pegasus Park Drive, Dallas, TX, US
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Taysha Gene Therapies, Inc., and the rating behind it. TSHA last traded at $5.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Taysha Gene Therapies, Inc.. Starting points for Taysha Gene Therapies, Inc.: EPS -$0.41, beta 1.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Taysha Gene Therapies, Inc.. Taysha Gene Therapies, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Taysha Gene Therapies, Inc.. Trailing twelve-month EPS for Taysha Gene Therapies, Inc. stands at -$0.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Taysha Gene Therapies, Inc.. Taysha Gene Therapies, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Taysha Gene Therapies, Inc. valued side by side against its closest peers. Taysha Gene Therapies, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Taysha Gene Therapies, Inc., and how their positions are changing. At a $1.61B market value, institutional positions materially move Taysha Gene Therapies, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Taysha Gene Therapies, Inc. executives and directors. Shares of Taysha Gene Therapies, Inc. have traded between $1.05 and $5.51 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Taysha Gene Therapies, Inc.. Taysha Gene Therapies, Inc. is a $1.61B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Taysha Gene Therapies, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Taysha Gene Therapies, Inc.. Coverage tracks Taysha Gene Therapies, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.